Arabinogalactan and hyaluronic acid in ophthalmic solution: Experimental effect on xanthine oxidoreductase complex as key player in ocular inflammation (in vitro study). (July 2020)

• Record Type: Journal Article
• Authors: Silvani, Ludovica; Bedei, Andrea; De Grazia, Giulia; Remiddi, Stefano
• Is Part Of: Experimental eye research. Volume 196(2020)
• Publication Date: 2020-07
• Subjects: Xanthine oxidoreductase -- Uric acid -- Ocular inflammation -- Corneal wounds -- Dry eye syndromes -- Arabinogalactan; AD artificial drop -- AG arabinogalactan -- DED dry eye disease -- HA hyaluronic acid -- P panthenol -- ROS reactive oxygen species -- T trehalose -- vE vitamin E-TPGS -- XDH xanthine deydrogenase -- X Xanthine -- XDH/XO intermediate form -- XO xanthine oxidase -- XOR xanthine oxidoreductase; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2020.108058
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Dry eye syndrome is a common disease associated to eyes inflammation, irritation and tear film instability. The enzymatic complex of xanthine oxidoreductase (XOR) is involved in the generation of reactive oxygen species (ROS) and uric acid that, in the end, can cause reperfusion injuries, irritation and pathological conditions. Furthermore, in the eye, it has been proposed that oxygen free radicals might play a significant role in retinal ischemic damage. A new artificial drop formulation based on arabinogalactan and hyaluronic acid has been proposed in this article. The uric acid and the ROS formation have been monitored. The effect of the arabinogalactan, the hyaluronic acid and their mixture has been studied. The arabinogalactan entails a uric acid and ROS reduction of 27% and 38% respectively; no significant reduction of uric acid or ROS has been observed after the addition of hyaluronic acid alone. Notably the combination of arabinogalactan and hyaluronic acid involves the reduction of uric acid and ROS equal to 38% and 62%, namely. This study demonstrates that this artificial drop formulation can markedly reduce the uric acid and ROS formation in vitro ; thus, the use of this formulation may contribute in the resolution of the dry eye syndrome. Highlights: Arabinogalactan (AG) and hyaluronic acid (HA) artificial drops (AD) was studied. AG entails uric acid (UA) and ROS reduction of 27% and 38%. HA involves no statically significant reduction of uric acid or ROS. AG and HA combination involves the reduction of UA and ROS equal to 38% and 62%.